Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study

J. Veselka, D. Zemánek, P. Hájek, M. Malý, R. Adlová, L. Martinkovičová, D. Tesař

. 2009 ; 104 (5) : 630-633.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc11016610

Both randomized and observational studies have suggested that pretreatment with statins may reduce the incidence of periprocedural myocardial infarction (PMI) in patients with stable angina during elective percutaneous coronary intervention (PCI). The purpose of this randomized study (Clinical Trial Registration No. NCT00469326) was to investigate the effect of 2-day atorvastatin therapy on the incidence of PMI in patients with stable angina pectoris undergoing elective PCI. A total of 200 patients with stable angina pectoris who were not taking statins and who had been referred for PCI were enrolled and randomized (ratio 1:1) to a 2-day pretreatment regimen with atorvastatin 80 mg/day and subsequent PCI or immediate PCI. The serum concentration of creatine kinase-MB mass and troponin I were measured before and 16 to 24 hours after PCI. The incidence of PMI was assessed using established criteria. Of the patients, 10% in the atorvastatin group and 12% in the control group had a postprocedural creatine kinase-MB mass elevation > or =3 times the upper limit of normal (p = 0.65). The incidence of PMI as determined by the postinterventional release of troponin I > or =3 times the upper limit of normal was 17% in the atorvastatin group and 16% in the control group (p = 0.85). The median creatine kinase-MB mass peak after PCI was 1.46 ng/ml (interquartile range 0.83 to 2.52) in the atorvastatin group and 1.40 ng/ml (interquartile range 0.90 to 2.54) in the control group (p = 0.70). The median peak troponin I level after PCI was 0.100 ng/ml (0.096 to 0.385) in the atorvastatin group and 0.100 ng/ml (0.60 to 0.262) in the control group (p = 0.54). On multivariate analysis, the only independent predictor of PMI was patient age (odds ratio 1.09, 95% confidence interval 1.025 to 1.159, p = 0.006). In conclusion, in the present study 2-day pre-PCI therapy with atorvastatin did not reduce the occurrence of PMI in patients with stable angina pectoris undergoing elective PCI.

Citace poskytuje Crossref.org

000      
03858naa 2200457 a 4500
001      
bmc11016610
003      
CZ-PrNML
005      
20121221095152.0
008      
110628s2009 xxu e eng||
009      
AR
024    __
$a 10.1016/j.amjcard.2009.04.048 $2 doi
035    __
$a (PubMed)19699335
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Veselka, Josef, $d 1965- $7 pna2005261820
245    10
$a Effect of two-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following elective percutaneous coronary intervention: a single-center, prospective, and randomized study / $c J. Veselka, D. Zemánek, P. Hájek, M. Malý, R. Adlová, L. Martinkovičová, D. Tesař
314    __
$a Department of Cardiology, CardioVascular Center, University Hospital, Charles University Motol Medical School I, Prague, Czech Republic. veselka.josef@seznam.cz
520    9_
$a Both randomized and observational studies have suggested that pretreatment with statins may reduce the incidence of periprocedural myocardial infarction (PMI) in patients with stable angina during elective percutaneous coronary intervention (PCI). The purpose of this randomized study (Clinical Trial Registration No. NCT00469326) was to investigate the effect of 2-day atorvastatin therapy on the incidence of PMI in patients with stable angina pectoris undergoing elective PCI. A total of 200 patients with stable angina pectoris who were not taking statins and who had been referred for PCI were enrolled and randomized (ratio 1:1) to a 2-day pretreatment regimen with atorvastatin 80 mg/day and subsequent PCI or immediate PCI. The serum concentration of creatine kinase-MB mass and troponin I were measured before and 16 to 24 hours after PCI. The incidence of PMI was assessed using established criteria. Of the patients, 10% in the atorvastatin group and 12% in the control group had a postprocedural creatine kinase-MB mass elevation > or =3 times the upper limit of normal (p = 0.65). The incidence of PMI as determined by the postinterventional release of troponin I > or =3 times the upper limit of normal was 17% in the atorvastatin group and 16% in the control group (p = 0.85). The median creatine kinase-MB mass peak after PCI was 1.46 ng/ml (interquartile range 0.83 to 2.52) in the atorvastatin group and 1.40 ng/ml (interquartile range 0.90 to 2.54) in the control group (p = 0.70). The median peak troponin I level after PCI was 0.100 ng/ml (0.096 to 0.385) in the atorvastatin group and 0.100 ng/ml (0.60 to 0.262) in the control group (p = 0.54). On multivariate analysis, the only independent predictor of PMI was patient age (odds ratio 1.09, 95% confidence interval 1.025 to 1.159, p = 0.006). In conclusion, in the present study 2-day pre-PCI therapy with atorvastatin did not reduce the occurrence of PMI in patients with stable angina pectoris undergoing elective PCI.
590    __
$a bohemika - dle Pubmed
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a angina pectoris $x terapie $7 D000787
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a kyseliny heptylové $x aplikace a dávkování $7 D006538
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x aplikace a dávkování $7 D019161
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a multivariační analýza $7 D015999
650    _2
$a infarkt myokardu $x prevence a kontrola $7 D009203
650    _2
$a prospektivní studie $7 D011446
650    _2
$a pyrroly $x aplikace a dávkování $7 D011758
650    _2
$a troponin I $x krev $7 D019210
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zemánek, David, $d 1972- $7 xx0079099
700    1_
$a Hájek, Petr $7 xx0071248
700    1_
$a Malý, Martin, $d 1966- $7 mzk2004241073
700    1_
$a Adlová, Radka $7 xx0139523
700    1_
$a Martinkovičová, Lucia. $7 _AN033108
700    1_
$a Tesař, David $7 xx0081874
773    0_
$t American Journal of Cardiology $w MED00000236 $g Roč. 104, č. 5 (2009), s. 630-633
910    __
$a ABA008 $b x $y 2
990    __
$a 20110720115208 $b ABA008
991    __
$a 20121221095236 $b ABA008
999    __
$a ok $b bmc $g 864023 $s 726391
BAS    __
$a 3
BMC    __
$a 2009 $x MED00000236 $b 104 $c 5 $d 630-633 $m The American journal of cardiology $n Am J Cardiol
LZP    __
$a 2011-3B09/BBjvme

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé